HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nencioni, A. Articles by Brossart, P. Search for Related Content PubMed PubMed Citation Articles by Nencioni, A. Articles by Brossart, P.

Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status

^a Massachusetts Institute of Technology, Center for Cancer Research, Cambridge, Massachusetts, USA;
^b Department of Internal Medicine, University of Genova, Genova, Italy;
^c Department of Hematology, Oncology and Immunology, University of Tübingen, Tübingen, Germany

Key Words. Dendritic cells • Tumor antigens • Vaccinations

Correspondence: Peter Brossart, M.D., Department of Hematology, Oncology and Immunology, University of Tübingen, Otfried-Müller Str. 10, D-72076 Tübingen, Germany. Telephone: 49-7071-298-2726; Fax: 49-7071-295709; e-mail: peter.brossart{at}med.uni-tuebingen.de

Dendritic cells (DCs) are specialized antigen-presenting cells whose immunogenicity leads to the induction of antigen-specific immune responses. DCs can easily be generated ex vivo from peripheral blood monocytes or bone marrow/circulating hematopoietic stem cells cultured in the presence of cytokine cocktails. DCs have been used in numerous clinical trials to induce antitumor immune responses in cancer patients. The studies carried out to date have demonstrated that DCs pulsed with tumor antigens can be safely administered, and this approach produces antigen-specific immune responses. Clinical responses have been observed in a minority of patients. It is likely that either heavy medical pretreatment or the presence of large tumor burdens (or both) is among the causes that impair the benefits of vaccination. Hence, the use of DCs should be considered in earlier stages of disease such as the adjuvant setting. Prospective applications of DCs extend to their use in allogeneic adoptive immunotherapy to specifically target the graft versus tumor reaction. DCs continue to hold promise for cellular immunotherapy, and further investigation is required to determine the clinical settings in which patients will most benefit from the use of this cellular immune adjuvant.

This article has been cited by other articles:

				N. Cools, P. Ponsaerts, V. F. I. Van Tendeloo, and Z. N. Berneman Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells J. Leukoc. Biol., December 1, 2007; 82(6): 1365 - 1374. [Abstract] [Full Text] [PDF]

				A. Landi, L. A. Babiuk, and S. van Drunen Littel-van den Hurk High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer J. Leukoc. Biol., October 1, 2007; 82(4): 849 - 860. [Abstract] [Full Text] [PDF]

				S. S. Farag DC therapy? Let the natural killer answer Blood, September 15, 2005; 106(6): 1892 - 1892. [Full Text] [PDF]

				C. Fauriat, A. Moretta, D. Olive, and R. T. Costello Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients Blood, September 15, 2005; 106(6): 2186 - 2188. [Abstract] [Full Text] [PDF]

				D. Dorfel, S. Appel, F. Grunebach, M. M. Weck, M. R. Muller, A. Heine, and P. Brossart Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA Blood, April 15, 2005; 105(8): 3199 - 3205. [Abstract] [Full Text] [PDF]